Trial Profile

Neoadjuvant Durvalumab (MEDI4736) Plus Docetaxel, Oxaliplatin, S-1 (DOS) Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient (pMMR) Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 01 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Docetaxel (Primary) ; Durvalumab (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Oxaliplatin (Primary) ; Tremelimumab (Primary)
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
Focus Adverse reactions; Therapeutic Use

26 Dec 2023 Planned End Date changed from 30 Apr 2023 to 30 Apr 2025.
26 Dec 2023 Planned primary completion date changed from 30 Apr 2023 to 30 Apr 2025.
21 Jan 2023 Interim Results (As of SEP 2022, n=40) efficacy, presented at the 2023 Gastrointestinal Cancers Symposium

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com